New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
SBIO ETF · ALPS Medical Breakthroughs ETF
The SBIO Exchange Traded Fund (ETF) is provided by ALPS. It is built to track an index: S-Network Medical Breakthroughs Index. The SBIO ETF provides physical exposure, so by buying it you actually own parts of all the underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 3/13/2026, 1:30 PM UTC
LIVE
CLOSED
This fund is part ofTomorrow's Treatments1M perf.-1.75%
Last price
$49.81
1M perf.
+0.50%
1M flows
+€1.1M
AuM
€116M
E/R
0.5%
Rating
ESG Consensus®
SBIO
$49.81
Performance & flows
Segment for quartile rank
December 15, 2025 → March 13, 2026
Create a free account to view the flows graph
SBIO
$49.88
-1.79%
Tomorrow's Treatments
+0.53%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +0.50%  | -1.79%  | +63.59%  | +84.39% | -5.41% | -3.33% | -2.44% | -2.44% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/13/2026
$49.88
1D NAV change
-0.70%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
N/A
Inception date
12/30/2014
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Fund
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the S-Network Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -1.79% | +63.59% | +84.39% | -5.41% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
S-Network Medical Breakthroughs Index NTR - USD
Index ticker
PMBITR Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
ALPS
ALPS ID Card
Number of funds
23
Total AuM
€16.4B
Expense ratio range
0.35% - 1%
Average expense ratio
0.5409%
Top 5 funds by ALPS
| AuM | ||
|---|---|---|
AMLP | Alerian MLP ETF | €10.39B |
SMTH | ALPS Smith Core Plus Bond ETF | €2.2B |
SDOG | ALPS Sector Dividend Dogs ETF | €1.16B |
EQL | ALPS Equal Sector Weight ETF | €568M |
IDOG | ALPS International Sector Dividend Dogs ETF | €428M |
Frequently asked questions about SBIO
What does ALPS Medical Breakthroughs ETF, SBIO, invest in?
SBIO is a Passive ETF. This ETF provides exposure to Mid and Small-Cap US Equities.
Which benchmark or index does SBIO replicate?
SBIO tracks the S-Network Medical Breakthroughs Index NTR - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of SBIO?
SBIO carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.
When was SBIO launched?
SBIO was introduced to the market on December 30, 2014. It trades on United States
Who is the ETF issuer of SBIO?
ALPS Medical Breakthroughs ETF, SBIO, is provided by ALPS. Learn more about ALPS here.
What is the current assets under management (AUM) of SBIO?
SBIO oversees €116M in assets as of March 13, 2026.
How has SBIO performed lately?
Based on data from March 13, 2026, SBIO returned 0.50% over the past month, -1.79% over the last three months and -2.44% year-to-date.
What are the latest inflows or outflows for SBIO?
As of March 13, 2026, SBIO recorded net flows of +€1.1M over the last month and +€7.8M year-to-date.
Does SBIO distribute dividends?
SBIO follows a distributing dividend policy, meaning it pays out income to investors.
What is the base currency of SBIO?
The base currency of SBIO is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
